Locally Advanced or Metastatic (ASTX029)

Study Information

Status: Active, Recruiting

Study Details

View study details on clinicaltrials.gov.

Locations

San Francisco

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

Description

A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

Location: CPMC (San Francisco)

Please contact: clinicalresearch@sutterhealth.org about study ASTX029

This trial is open for patients with one of the following, for whom standard approved therapies are not available.

Cohort A: NRAS-mutant melanoma.

Cohort B: KRAS-mutant or KRAS-amplified non-small cell lung cancer (NSCLC).

Cohort C: BRAF V600-mutant cancers (non-colorectal cancers).

Cohort D: BRAF-fusion cancers.

Cohort E: Gynecological cancers with alterations in the MAPK pathway.

Cohort F: Tumors characterized by other gene aberrations that upregulate the MAPK signal pathway.

Principal Investigator

Kevin Kim, MD

Related Studies

The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity

Using EHR from a large healthcare system in Northern CA, we will study the impact of smoking, comorbidities, race on COVID-19 infection and disease severity.

Investigator: Jiang Li, Ph.D., MPH